
Advent to take Mediq private for €775m
Advent International has announced plans to delist Dutch pharma company Mediq from the Euronext Amsterdam, valuing the company at €775m.
The acquisition will be made through AI Garden BV, wholly owned by Advent. The GP is offering €13.25 (cum dividend) in cash for all issued and outstanding Mediq shares. This represents a 53% premium on last week's closing share price and a 47% premium on the three-month average.
Existing Mediq shareholders Templeton Investment Counsel and Silchester International Investors, which own a combined share of 20.2%, will accept and support the offer. Mediq's board also approved and recommended Advent's offer.
The parties involved are currently seeking all necessary approvals and clearances, and are planning to go ahead with the process in Q4 2012.
Following the transaction, Advent will follow a buy-and-build strategy for Mediq, focusing on its direct and institutional distribution channel, in order to strengthen its position in the Dutch pharma market.
Advent plans to leave Mediq's two-tier board structure in place; the current management board will remain unchanged following the transaction. The GP announced there would be no redundancies as a direct consequence of the takeover.
Company
Mediq is a Dutch pharmaceuticals, medical devices and care services company headquartered in Utrecht. Founded in 1899, the business delivers products and services directly to individuals, via hospitals, nursing homes and other healthcare institutions.
In 2011, Mediq recorded sales of €2.7bn. It is currently listed on the Euronext Amsterdam.
People
Tom Allen and Bram Grimmelt led the deal on behalf of Advent. Sjoerd van Keulen chairs Mediq's supervisory board and Marc van Gelder is the company's CEO.
Advisers
Equity – Deutsche Bank (M&A); Rabobank (M&A); BNP Paribas (M&A); Marlborough Partners (Debt advisory); Freshfields Burckhauser Deringer (Legal).
Company – ING Bank (M&A); Allen & Overy (Legal).
Supervisory Board – ABN Amro (M&A).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater